Open AccessThyrotoxicosis With Pegylated Interferon Alfa-2b
Author(s) -
Sarah Lowndes,
Ruth Asher,
Mark R. Middleton
Publication year - 2010
Publication title -
archives of dermatology
Language(s) - English
Resource type - Journals
eISSN - 1538-3652
pISSN - 0003-987X
DOI - 10.1001/archdermatol.2010.306
Subject(s) - medicine , interferon alfa , pegylated interferon , alpha interferon , propylthiouracil , interferon , disease , melanoma , adjuvant therapy , adjuvant , stage (stratigraphy) , cancer , gastroenterology , oncology , immunology , ribavirin , thyroid , virus , hepatitis c virus , paleontology , cancer research , biology
Despite adequate surgery, a diagnosis of stage III melanoma carries a high risk of relapse, and hence mortality. Interferon alfa is the only treatment that has currently been shown to alter the natural history of the disease, delaying relapse-free survival, particularly in patients with micrometastatic disease. There is also recent evidence of a prognostic advantage conferred by the development of autoimmune conditions in patients receiving adjuvant interferon therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom